PeruzeIt

Sanders will direct Dynavax's product development programs, including pre-clinical, process development, clinical, and regulatory activities. Marty has worked on products across a broad range of therapeutic categories, including rheumatology, allergy, immunology, dermatology, oncology and infectious disease. Dynavax's TLR9-based technologies, both in managing the development of our advanced product candidates and other areas where this powerful technology has the potential to reprogram the immune system and change the way diseases are treated," said Dino Dina, MD, President and Chief Executive Officer. About Dynavax Dynavax Technologies Corporation discovers, develops, and intends to commercialize innovative TLR9 agonist-based products to treat and prevent infectious diseases, allergies, cancer, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways.

Read the full story at FOXBusiness

Posted Under: Allergy and Immunology, Internal Medicine, Microbiology